Harry P. Erba, MD, PhD, Duke Cancer Institute
Articles
Treatment Options for High-Risk Polycythemia Vera
Harry P. Erba, MD, PhD, Duke Cancer Institute;Krisstina Gowin, DO, University of Arizona Cancer Center;Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center;Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center;Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
July 7th 2020Read More
Management of Low-Risk Polycythemia Vera
Harry P. Erba, MD, PhD, Duke Cancer Institute;Krisstina Gowin, DO, University of Arizona Cancer Center;Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center;Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center;Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
July 7th 2020Read More
Polycythemia Vera: Monitoring Patients
Harry P. Erba, MD, PhD, Duke Cancer Institute;Krisstina Gowin, DO, University of Arizona Cancer Center;Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center;Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center;Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
July 7th 2020Read More
Polycythemia Vera: Risk Assessment
Harry P. Erba, MD, PhD, Duke Cancer Institute;Krisstina Gowin, DO, University of Arizona Cancer Center;Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center;Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center;Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
July 7th 2020Read More
Polycythemia Vera: Prognostic Markers
Harry P. Erba, MD, PhD, Duke Cancer Institute;Krisstina Gowin, DO, University of Arizona Cancer Center;Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center;Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center;Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
July 7th 2020Read More
Polycythemia Vera: Bone Marrow Biopsies
Harry P. Erba, MD, PhD, Duke Cancer Institute;Krisstina Gowin, DO, University of Arizona Cancer Center;Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center;Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center;Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
July 7th 2020Read More
Polycythemia Vera: Diagnostic Work-up
Harry P. Erba, MD, PhD, Duke Cancer Institute;Krisstina Gowin, DO, University of Arizona Cancer Center;Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center;Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center;Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
July 7th 2020Read More
Characterization of Myeloproliferative Neoplasms
Harry P. Erba, MD, PhD, Duke Cancer Institute;Krisstina Gowin, DO, University of Arizona Cancer Center;Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center;Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center;Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
July 7th 2020Read More
Latest Updated Articles
Published: September 27th 2024 | Updated: October 3rd 2024
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: May 27th 2024 | Updated: September 13th 2024
A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma
Published: August 22nd 2024 | Updated: August 29th 2024
Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors
Published: August 6th 2024 | Updated: August 19th 2024
Long-term Follow-up of Selinexor Maintenance for Patients With TP53wt Advanced or Recurrent Endometrial Cancer: A Prespecified Subgroup Analysis From the Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
